Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, regulatory-update, financials
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K on 9/4/24, updating corporate info and financial statements.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on September 4, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at One World Trade Center, New York, NY, and its primary business in Pharmaceutical Preparations.
Why It Matters
This filing provides an update on Axsome Therapeutics' corporate and financial reporting, which is crucial for investors to stay informed about the company's status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine corporate filing with no new material financial or operational information that would inherently increase risk.
Key Numbers
- 001-37635 — SEC File Number (Identifies the company's filing history with the SEC.)
- 45-4241907 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- September 04, 2024 (date) — Date of earliest event reported
- One World Trade Center, 22nd Floor (location) — Principal Executive Offices
- New York (location) — City of Principal Executive Offices
- 10007 (postal_code) — ZIP code of Principal Executive Offices
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 04, 2024.
Where are Axsome Therapeutics, Inc.'s principal executive offices located?
Axsome Therapeutics, Inc.'s principal executive offices are located at One World Trade Center, 22nd Floor, New York, New York, 10007.
What is Axsome Therapeutics, Inc.'s Standard Industrial Classification code?
Axsome Therapeutics, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's telephone number?
The company's telephone number, including area code, is (212) 332-3241.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 9.9 · Accepted 2024-09-04 07:05:39
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20240904.htm (8-K) — 39KB
- axsm-ex99_1.htm (EX-99.1) — 20KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- 0000950170-24-103098.txt ( ) — 202KB
- axsm-20240904.xsd (EX-101.SCH) — 23KB
- axsm-20240904_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 4, 2024, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has acknowledged the resubmission of the Company's New Drug Application for AXS-07 for the acute treatment of migraine. The full text of the press release is filed as Exhibit 99.1 hereto, and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: September 4, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer